TY - JOUR
AU - Nishimura, Akihiko
AU - Xie, Junqing
AU - Kostka, Kristin
AU - Duarte-Salles, Talita
AU - Fernández Bertolín, Sergio
AU - Aragón, María
AU - Blacketer, Clair
AU - Shoaibi, Azza
AU - DuVall, Scott L.
AU - Lynch, Kristine E.
AU - Matheny, Michael E.
AU - Falconer, Thomas
AU - Morales, Daniel R.
AU - Conover, Mitchell M.
AU - Chan You, Seng
AU - Pratt, Nicole
AU - Weaver, James
AU - Sena, Anthony G.
AU - Schuemie, Martijn J.
AU - Reps, Jenna
AU - Reich, Christian G.
AU - Rijnbeek, Peter R.
AU - Ryan, Patrick B.
AU - Hripcsak, George
AU - Prieto-Alhambra, Daniel
AU - Suchard, Marc A.
PY - 2022
DA - September
TI - International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients
JO - Frontiers in Pharmacology
VL - 13
DO - https://doi.org/10.3389/fphar.2022.945592
AB - Purpose: Alpha-1 blockers, often used to treat benign prostatic hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storm release. The proposed treatment based on this hypothesis currently lacks support from reliable real-world evidence, however. We leverage an international network of large-scale healthcare databases to generate comprehensive evidence in a transparent and reproducible manner.
PB - Frontiers Media
UR - https://discovery.dundee.ac.uk/en/publications/d8d3f9b7-087b-4504-987c-54d5d0ea1383
KW - Coronavirus (COVID-19)
ER